Genetic testing for thousands of inherited conditions.

Inherited arrhythmias, cardiomyopathies, and familial lipid disorders share a critical trait: they are genetically determinable, often before symptoms appear. The genes responsible — SCN5A, MYBPC3, KCNQ1, KCNH2, MYH7, and others — carry variants that standard cardiac panels frequently miss because those panels typically screen only a pre-selected set of known variants, not the full gene sequence.

Whole genome sequencing reads the complete sequence of every cardiac gene, identifying the full spectrum of known pathogenic and likely-pathogenic variants. This matters because cardiovascular genetic conditions follow a cascade pattern: a confirmed variant in one family member has immediate, actionable implications for every first-degree relative — siblings, children, parents. The clinical value multiplies across the family.

For conditions like Hypertrophic Cardiomyopathy and Long QT Syndrome, early identification enables monitoring, lifestyle modification, and in some cases preventive treatment — before a cardiac event forces the question.

APOE4 is the most commonly searched neurological genetic marker — and for a reason most people understand without being told. Those who search for it have often watched a parent or grandparent with Alzheimer's and want to know their own risk before symptoms appear. The question is not abstract; it is personal, and it is urgent.

Knowing your neurological genetic profile changes what you can do with the years before any symptoms appear. APOE4 carrier status informs monitoring strategies, lifestyle decisions, and access to prevention programs and clinical trials that require genetic qualification. For Parkinson's, variants in LRRK2 and GBA not only identify risk — they are increasingly relevant as genotype-stratified therapies enter clinical development.

Beyond these high-profile genes, whole genome sequencing identifies variants associated with hereditary neuropathies, Huntington's disease, Fragile X syndrome, and rare neurological conditions that standard panels are not designed to test. A complete genetic picture does not change the nature of these conditions — but it gives you and your physician the information to plan rather than react.

Metabolic genetic conditions are among the most commonly undiagnosed — not because they are rare, but because their symptoms overlap with conditions that are far more commonly tested for. Gilbert Syndrome affects an estimated 8–10% of the population. Hereditary hemochromatosis is the most common genetic disorder in populations of Northern European descent. MTHFR variants, relevant to folate metabolism and homocysteine levels, generate more than 200,000 monthly searches in the US alone.

The pattern is consistent: patients with fatigue, unexplained jaundice, or abnormal lab results that don't fit any standard diagnosis. GPs who dismiss or attribute symptoms to lifestyle. Tests that return borderline numbers without identifying the underlying cause. These are the conditions where a genetic answer changes the clinical conversation immediately.

Whole genome sequencing reads the full sequence of every gene involved in metabolic function — not just the most common variants in the most commonly tested genes. For conditions like hemochromatosis, identifying the HFE genotype precisely (C282Y homozygous vs. compound heterozygous) determines treatment urgency, monitoring frequency, and whether family members should be tested.

Autoimmune and inflammatory conditions occupy an often-frustrating middle ground: there is a clear genetic component — HLA-DRB1 in rheumatoid arthritis, NOD2 in Crohn's disease, HLA-DQ2 and DQ8 in celiac — yet most patients receive their diagnosis through clinical presentation and elimination, without their genetic architecture ever being confirmed.

This matters for several reasons. In conditions like rheumatoid arthritis, genetic subtype affects treatment response — patients with certain HLA profiles respond differently to biologic therapies. In celiac disease, a negative HLA-DQ2/DQ8 result effectively rules out the condition. In Crohn's disease, genetic markers inform the distinction between Crohn's and ulcerative colitis, which have different treatment implications. The genetic result does not just confirm the diagnosis — it changes what happens next.

Cystic fibrosis and Spinal Muscular Atrophy are included here because the most common clinical question is carrier status: understanding whether you carry one copy of a pathogenic variant, and whether a partner should also be tested before family planning. Whole genome sequencing confirms carrier status with complete CFTR and SMN1 coverage — not a targeted screen of the most common variants.